24/7
Buzz
Startups
VC
AI
Innovation
Opinions
Events
Promising Startups 2026
2026 VC Survey
Boarding Pass
CTalk
BiblioTech
Corporate
Appointments
Tech Gateways
@Finance
Ctech Testimonials
Projects
About
Newsletter
Contact us
Facebook
Twitter
ACCESSIBILITY
by
Homepage
Copaxone
Tags search
HOME
24/7
buzz
STARTUPS
VC
AI
Innovation
OPINIONS
EVENTS
Projects
ABOUT
teram of use
Privacy Policy
NEWSLETTER
SEARCH
CONTACT US
ACCESSIBILITY
24/7
Headlines
18:20
The World Cup warning: Riots don’t start in the streets. They start online
18:07
“There’s a price where you have to say yes”: CyberArk founder on the $25 billion Palo Alto deal
14:18
"If there is no significant change, we will see a 25%-30% reduction in high-tech's workforce"
13:32
“There is no better solution for Zim than the one we created”
More stories
Buzz
Most popular
Daily
Weekly
1
"If an engineer in Ireland costs 20% less, it is clearly part of the consideration when deciding where to expand"
2
Iron Dome and Iron Beam maker Rafael unveils new weapon against the drone threat
3
Echo: “Employees have become very good at identifying performative culture”
4
"If there is no significant change, we will see a 25%-30% reduction in high-tech's workforce"
5
More than 50 years after its debut, Israel's Kfir fighter jet gets a new lease on life
More news
Copaxone
4 stories about Copaxone
Teva’s Stock Drops After Approval of Copaxone Competitors
08.10.17
|
Lilach Baumer
A day after Mylan announced FDA approval for its generic versions of Copaxone, drug companies Synthon and Alvogen announce European approval for their 40 mg/ml generic versions of Teva's blockbuster drug
Teva Loses Copaxone Market Exclusivity
04.10.17
|
Lilach Baumer
Rival Mylan received FDA approval for its generic versions of Copaxone, Teva’s flagship drug
New CEO to Break Teva’s Copaxone Habit
11.09.17
|
Sophie Shulman, Dror Reich
Troubled drugmaker says new CEO must work to quickly regain its financial credibility
With Bloated Debt, Teva Looks to Sell Assets
10.08.17
|
Eli Shimony and Gil Kalian
The generic drugmaker said it is looking to sell Medis, an Iceland-based company it bought in 2016
Previous Articles